What sector does WAKAMOTO PHARMACEUTICAL CO.,LTD. belong to?

WAKAMOTO PHARMACEUTICAL CO.,LTD. operates in the Pharmaceuticals sector, specifically the Pharmaceutical industry, and is listed on the US markets.

What is the current share price of 4512?

As of the latest available quote, 4512 traded at ¥290.00. This price is delayed and cached for about 15 minutes.

What is the P/E ratio of 4512?

WAKAMOTO PHARMACEUTICAL CO.,LTD. has a price-to-earnings (P/E) ratio of about 44.27. The P/E ratio compares the share price to earnings per share and is most useful when compared with sector peers and the company's own history.

What is the market capitalisation of 4512?

The market capitalisation of WAKAMOTO PHARMACEUTICAL CO.,LTD. is approximately ¥10.08B.

Is WAKAMOTO PHARMACEUTICAL CO.,LTD. profitable?

For its latest reported financial year, WAKAMOTO PHARMACEUTICAL CO.,LTD. recorded a net profit margin of about 2.29%.

Does 4512 pay a dividend?

WAKAMOTO PHARMACEUTICAL CO.,LTD. does not currently show a dividend yield in our data.

What is the return on equity (ROE) of 4512?

WAKAMOTO PHARMACEUTICAL CO.,LTD. has a return on equity (ROE) of about 1.92%. ROE measures how much profit a company generates relative to shareholders' equity.

What is the 52-week high and low of 4512?

Over the past 52 weeks, 4512 has traded between a low of ¥240.00 and a high of ¥380.00.

WAKAMOTO PHARMACEUTICAL CO.,LTD.

4512 TSE Pharmaceuticals Pharmaceutical

TSE Standard

¥290.00

+0.00%

Delayed · cached 15 min

Fair value analysis

4512

WAKAMOTO PHARMACEUTICAL CO.,LTD.

¥290.00

Close used for this calculation

¥141.24Fair value

Financial DNA Score

Profitability · Returns · Balance Sheet · Efficiency · Growth

25/100

Profitability6/25

Returns1/25

Balance Sheet13/25

Efficiency5/25

Growth4/25

Weak

Quality radar

Consensus fair value

¥141.24

Above FV

▼ -51.3% against the close used

Model range ¥7.91 – ¥225.39

The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear¥7.91Fair value¥141.24Bull¥225.39

FairClose

52-week traded range

52W low ¥242.0052W high ¥364.00

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading above the consensus fair value

WAKAMOTO PHARMACEUTICAL CO.,LTD. closed at ¥290.00, 105.3% above the consensus fair value of ¥141.24 drawn from 9 valuation models.

Financial DNA score 25/100 — Weak. P/E of 44.3x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation

¥122.58

-57.7%

Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10

g=8%, r=10%, tg=3%, n=10yr

Graham Number

¥225.39

-22.3%

√(22.5 × EPS × BVPS)

EPS=6.54, BVPS=345.24 · outside Graham range (P/E 44.3, P/B 0.8) — asset-light, treat as a rough floor

P/E Fair Value

¥130.80

-54.9%

EPS × 20x (sector P/E)

EPS=6.54, Sector P/E=20x

Peter Lynch (PEG)

¥7.91

-97.3%

EPS × Growth% (PEG = 1 is fair)

EPS=6.54, g=1.2%

EV/EBITDA

¥190.64

-34.3%

(EBITDA × 10x − Net Debt) ÷ Shares

EBITDA=698.47M

Dividend Discount (DDM)

¥44.74

-84.6%

D1 ÷ (r − g) where D1 = D0×(1+g)

D0=3.51, r=10%, g=2%

Book Value (P/B)

¥66.29

-77.1%

BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]

BVPS=345.24, ROE=1.9%, g=3%, r=10%

Reverse DCF

¥290.00

+0.0%

Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV

Implied: 17.9% | Historical: -1.2%

Margin of Safety

¥119.69

-58.7%

Avg(DCF, Graham, P/E) × 75% (25% safety buffer)

Avg fair value=159.59, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Fair value analysis

Consensus fair value

Price target range & 52-week position

Valuation summary

All valuation models

Equity Timer